Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (221-230 of 313) with videos related to

Pageof 32
Sort By:
International Journal of Cardiology|August 27, 2018
Incremental prognostic value of renal function for stroke prediction in atrial fibrillationEmily C O'Brien, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
Circulation|July 1, 2016
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|August 10, 2016
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF TrialSreekanth Vemulapalli, Anne S Hellkamp, W Schuyler Jones, et al.
The American Journal of Medicine|November 27, 2016
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationPaul L Hess, Sunghee Kim, Gregg C Fonarow, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 32

Showing results (221-230 of 313) with videos related to

Sort By:
Pageof 32
International Journal of Cardiology|August 27, 2018
Incremental prognostic value of renal function for stroke prediction in atrial fibrillationEmily C O'Brien, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
Circulation|July 1, 2016
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|August 10, 2016
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF TrialSreekanth Vemulapalli, Anne S Hellkamp, W Schuyler Jones, et al.
The American Journal of Medicine|November 27, 2016
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationPaul L Hess, Sunghee Kim, Gregg C Fonarow, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 32